• Ongoing phase 1/2 study with up to 64 patients
  • The patients have received 1–4 earlier lines of therapy including IMiDs and PIs
  • Demonstrates how melflufen can be administered as a combination therapy with daratumumab or bortezomib
  • Explores potential for using melflufen in earlier lines of therapy
  • May significantly increase melflufen’s market potential as a combination therapy
  • Started in Q2 2018, data reporting from both treatment arms reported was done during 2019. The recruitment to daratumumab arm was completed in Q4 2019 while the recruitment to the bortezomib arm is expected to be completed in H1 2021